Evidence map›Paper›PMID 25519927›Full record

ArticleAnnals of surgical oncology2015

Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.

Amanda B Cooper, Rebecca Slack, David Fogelman, Holly M Holmes, Maria Petzel, Nathan Parker, Aparna Balachandran, Naveen Garg, An Ngo-Huang, Gauri Varadhachary and 7 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02680990 nacompletednot on this map

Prehabilitation for Patients With Aggressive Gastrointestinal Cancers Undergoing Neoadjuvant Therapy

TypeinterventionalSponsorMilton S. Hershey Medical CenterRan2015 to 2017Enrolled14ConditionsPancreatic Adenocarcinoma, Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal JunctionArmsBand Together, Exercise Education
NCT05899205 recruitingnot on this mapstarted 2021, after this paper: background citation

Patient Recorded Indexing Measurements

TypeobservationalSponsorAcademisch Ziekenhuis MaastrichtRan2021 to 2027Enrolled300ConditionsCachexia, Cancer, Weight, Body
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Approaches to Assessment of Muscle Mass and Myosteatosis on Computed Tomography: A Systematic Review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2019
    Pooled it
  6. Pooled it
  7. Trial
  8. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2024
    Trial
  9. Body Composition Is a Predictor for Postoperative Complications After Gastrectomy for Gastric Cancer: a Prospective Side Study of the LOGICA Trial.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022
    Trial
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Amanda B CooperDepartment of Surgery, Penn State Hershey Medical Center, Hershey, PA, USA.
Rebecca Slack
David Fogelman
Holly M Holmes
Maria Petzel
Nathan Parker
Aparna Balachandran
Naveen Garg
An Ngo-Huang
Gauri Varadhachary
Douglas B Evans
Jeffrey E Lee
Thomas Aloia
Claudius Conrad
Jean-Nicolas Vauthey
Jason B Fleming
Matthew H G Katz

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672
6 · The paper itself

Abstract

backgroundLittle is known about changes in body composition that may occur during neoadjuvant therapy for pancreatic cancer. This study was designed to characterize these changes and their potential relationships with therapeutic outcomes.

methodsThe study population consisted of patients with potentially resectable pancreatic cancer treated on a phase II trial of neoadjuvant chemotherapy and chemoradiation. Skeletal muscle and adipose tissue compartments were measured before and after administration of neoadjuvant therapy using SliceOMatic software (TomoVision, 2012) and protocol-mandated CT scans. Sarcopenia was defined using gender-adjusted norms.

resultsAmong 89 eligible patients, 46 (52 %) patients met anthropometric criteria for sarcopenia prior to the initiation of neoadjuvant therapy. Further depletion of skeletal muscle, visceral adipose tissue, and subcutaneous adipose tissue occurred during neoadjuvant therapy, but these losses did not preclude the performance of potentially curative surgery. Degree of skeletal muscle loss correlated with disease-free survival while visceral adipose loss was associated with overall and progression-free survival. However, completion of all therapy, including pancreatectomy, was the only independently significant predictor of outcome in a multivariate analysis of overall survival. DISCUSSION: These data suggest that body composition analysis of standard CT images may provide clinically relevant information for patients with potentially resectable pancreatic cancer who receive neoadjuvant therapy. Anthropometric changes must be considered in the design of preoperative therapy regimens, and further efforts should focus on maintenance of muscle and visceral adipose tissue in the preoperative setting.

Indexed as

PancreatectomyAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBody CompositionBody WeightCarcinoma, Pancreatic DuctalChemoradiotherapyChemotherapy, AdjuvantCisplatinClinical Trials, Phase II as TopicCombined Modality TherapyDeoxycytidineFollow-Up StudiesGemcitabineHumansNeoadjuvant TherapyCisplatinDeoxycytidineGemcitabine

Identifiers

PMID25519927
PMCPMC11831732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.